Product
Favezelimab
Aliases
MK-4280
4 clinical trials
7 indications
Indication
CancerIndication
MetastasisIndication
Hodgkin lymphomaIndication
lymphomaIndication
Non-HodgkinIndication
B-cellIndication
NSCLCClinical trial
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)Status: Active (not recruiting), Estimated PCD: 2025-06-28
Clinical trial
A Phase 1 Trial of MK-4280 as Monotherapy and in Combination With Pembrolizumab With or Without Chemotherapy or Lenvatinib (E7080/MK-7902) in Subjects With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2024-03-15
Clinical trial
LIGHTBEAM-U01 Substudy 01B: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2029-06-30
Clinical trial
A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2028-04-19